RSS

melanoma

Healthcare solutions provider, Novartis, has announced that the European Commission has approved its combination therapy, Tafinlar + Mekinist, for adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma. more

News

Approval has been granted for the third cohort of Prima BioMed’s Phase I clinical trial of IMP321 in combination with KEYTRUDA, being conducted in Australia. This cohort will recruit six patients with unresectable or metastatic melanoma. more

News

Study reveals drugs that can extend the lives of patients with skin cancer more

News

An immunotherapy clinical trial collaboration is to be undertaken by Immunocore and Eli Lilly and Company, exploring the use of Immunocore’s lead T-cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (L more

News

BioNTech RNA Pharmaceuticals and EUFETS will work with Siemens to produce a fully automated and digitalised production site, providing capacity for BioNTech’s personalised cancer vaccines to serve worldwide markets. more

News

Advances in the treatment of disease have recently taken another step forward with the discovery that a genetically engineered version of the virus that causes cold sores could be used in the treatment of skin cancer. more

News